Overdose
Conditions
Brief summary
The aims of this study are: (Aim 1) Identify sources of heterogeneous impacts of opioid prevention center (OPC) use on non-fatal and fatal overdose risk among individuals with histories of polysubstance use (PSU); (Aim 2) Estimate the impact of OPC use on treated psychiatric events among clients with histories of PSU, and; (Aim 3) Assess the barriers and facilitators of integrating mental health services into existing syringe service and OPC delivery models.
Detailed description
Aims 1 and 2 of this study will use secondary data to identify sources of heterogeneous impacts of OPC use on fatal and nonfatal overdose risk (Aim 1) and estimate the impact of OPC use on treated psychiatric events among clients with histories of PSU (Aim 2). Aim 3 of this study will use qualitative interviews with harm reduction staff to assess barriers and facilitators of integrating mental health services into existing syringe service and OPC delivery models.
Interventions
None listed
Sponsors
NYU Langone Health
Centers for Disease Control and Prevention
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Aims 1 and 2: * are 18 years of age or older; * engaged in syringe service program and/or overdose prevention center services in New York City in the past 30 days before the date of enrollment; * are able to complete assessments in English or Spanish; * are competent to give written informed consent at the time of the interview; * are able to provide informed consent; * self-report use of illicit opioids (e.g., heroin, fentanyl), illicit stimulants (e.g., powder cocaine, crack, methamphetamine), counterfeit prescription pills (defined as prescription pills obtained through the illicit drug market) or any injection drug use in the past 30 days, and * are able to participate for at least 6 months following enrollment. Aim 3 * are 18 years of age or older; * are employed by a harm reduction program; * are able to complete assessments in English; and * are able to provide informed consent.
Exclusion criteria
• Individuals not meeting the criteria detailed above for the respective Aims will not be eligible for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Fatal Overdose | Up to Month 12 | Incidence of fatal overdose will be derived from overdose mortality data from the NYC Office of the Chief Medical Examiner. |
| Incidence of Non-Fatal Overdose | Up to Month 12 | Incidence of nonfatal overdose will be assessed using hospitalization and emergency department data from the NYC Regional Health Information Exchange (RHIO) and Statewide Research and Planning Cooperative System (SPARCS). |
| Incidence of Psychiatric Services Utilization | Up to Month 12 | Psychiatric services utilization will be assessed from SPARCS, RHIO, and NYS Medicaid. |
Countries
United States
Contacts
CONTACTBennett Allen, PhD, MPA
PRINCIPAL_INVESTIGATORBennett Allen, PhD, MPA
NYU Langone Health
Outcome results
None listed